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 Introduction 
 Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) 
is contraindicated in stroke patients receiving oral anticoagulants  [1] . Knowledge of current 
medication is therefore necessary before commencing IVT. In the emergency setting, point-
of-care (POC) coagulation devices provide rapid international normalized ratio (INR) 
measurements  [2] . However, current POC devices that are used to monitor vitamin K antago-
nists are not always suitable for accurately measuring anticoagulant activity of the new oral 
anticoagulants (NOACs)  [3] . We report an ‘accidental’ thrombolysis in a stroke patient in 
whom treatment with apixaban, a NOAC that inhibits factor Xa (FXa), became apparent only 
after the completion of IVT.
 Case Report 
 An 83-year-old male with a history of arterial hypertension and diabetes developed acute 
right-sided hemiparesis and fluent aphasia (NIHSS score on admission: 4). He arrived at our 
hospital 45 min later. On admission, his blood pressure was 160/70 mm Hg; atrial fibrillation 
was detected on electrocardiography. Cranial computed tomography (cCT) revealed no early 
signs of cerebral ischemia or intracranial hemorrhage (ICH). The patient was unable to self-
report his drug history due to persisting aphasia. The INR measured by a commercial POC 
device was within normal range (1.00; normal 0.85–1.18). IVT (rt-PA 0.9 mg/kg) was initiated 
80 min after symptom onset and before all laboratory findings were received. Around 20 min 
after IVT had commenced, coagulation parameters were normal [including INR (1.10), 
thrombin time (18.8 s; normal 14–21), partial thromboplastin time (34.8 s, normal 23–36) 
and platelet counts]. A follow-up cCT ruled out IVT-induced ICH and the patient fully recovered 
within 48 h (NIHS score: 0). At this stage, he was able to report regular intake of apixaban 
(Eliquis ® , 2.5 mg t.i.d.) since April 2014 due to atrial fibrillation. The last apixaban tablet had 
been taken 13.5 h before IVT.
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 Discussion 
 Stroke patients are frequently unable to report their drug history because of accompa-
nying neurologic symptoms such as aphasia or unconsciousness. This is especially prob-
lematic for those receiving oral anticoagulants, owing to the increased risk of ICH during IVT 
 [4] .
 The current report underlines the urgent need to develop POC devices specific for the 
rapid determination of the anticoagulatory effect of NOACs, similar to those used for vitamin 
K antagonists  [5] . Furthermore, it raises the question of whether NOAC plasma levels should 
be routinely measured prior to IVT, particularly considering the growing use of NOACs  [6] . 
Laboratory testing of NOAC plasma concentrations is time-consuming, and the lower 
threshold, which would allow ‘safe’ IVT, has not yet been established  [3] . Moreover, 24/7 
availability is restricted to large hospitals. Recent evidence suggests that the measurement of 
‘surrogate markers’ such as thrombin time or anti-FXa may enable the quantification of factor 
IIa and FXa inhibitors, respectively, although various confounding factors may impact the 
assay results  [7–9] .
 In summary, stroke patients with a considerable chance of receiving NOACs, e.g. those 
with known atrial fibrillation or a history of venous thrombosis, should be intensely screened 
prior to IVT, even if NOAC intake was excluded on an anamnestic basis.
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